C07D 311/30(20130101), A61K 31/352(20130101)
The bioflavonoid luteolin reduces amyloid-β peptide (Aβ) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic γ-secretase APP processing, and 2) promotes presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3α activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. To validate The findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble Aβ levels, reduced GSK-3 activity, and disrupted PS1-APP association.
Tan, Jun; Shytle, Doug; and Rezai-Zadeh, Kavon, "Treatment of glycogen synthase kinase-based disease" (2014). USF Patents. 138.
University of South Florida